Manchester scoring system
Scottish Cancer Network: Clinical Management Pathways
| BRCA1 | BRCA2 | COMBINED | |
| FAMILY HISTORY | |||
| FBC <30 | 6 | 5 | 11 |
| FBC 30-39 | 4 | 4 | 8 |
| FBC 40-49 | 3 | 3 | 6 |
| FBC 50-59 | 2 | 2 | 4 |
| FBC >59 | 1 | 1 | 2 |
| MBC <60 | 5 | 8 | 13 |
| MBC >59 | 5 | 5 | 10 |
| Ovarian <60* | 8 | 5 | 13 |
| Ovarian >59* | 5 | 5 | 10 |
| Pancreatic | 0 | 1 | 1 |
| Prostate <60 | 0 | 2 | 2 |
| Prostate >59 | 0 | 1 | 1 |
| BRCA Pathology Index Case | |||
|
Grade 3 triple –ve (ER -ve score = <4) |
4 | 0 | 4 |
| LCIS (no invasive cancer) | -4 | 0 | -4 |
| HER2 +ve | -4 | 0 | -4 |
*Ovarian
Include - Epithelial (endometriod, serous, clear cell, NOS), granulosa cell.
Exclude - mucinous, borderline and germ cell tumours except granulosa cell.
A combined score of 15 or more meets threshold for BRCA testing.
To calculate the Manchester score every individual in a direct lineage in a family affected with breast, ovarian, prostate or pancreatic cancer is given a score from the table above. These scores are summed to give the total Manchester score.